dna2 Antibody

What is DNA2 and what are its primary functions in cellular biology?

DNA2 (DNA replication helicase/nuclease 2) is a conserved protein with dual helicase and nuclease activities that plays crucial roles in maintaining genomic stability. The human DNA2 protein is approximately 120.4 kilodaltons in mass and may also be known by alternative names including DNA2L, hDNA2, DNA replication ATP-dependent helicase/nuclease DNA2, and DNA replication ATP-dependent helicase-like homolog . DNA2 primarily functions in the maintenance of both mitochondrial and nuclear DNA stability by processing intermediate 5' flap structures that occur during DNA replication and long-patch base excision repair in mitochondria . It interacts with DNA polymerase gamma and stimulates its activity, thus facilitating efficient DNA replication. DNA2 also has a significant role in homologous recombination repair by facilitating the recruitment of repair factors like Rad51 to double-strand breaks (DSBs) and preparing DNA ends for invasion of homologous duplex through its nuclease activity .

What are the structural and functional domains of DNA2 protein that antibodies might target?

DNA2 protein contains two main functional domains that are critical to its cellular activities. The protein includes a DNA replication nuclease domain and a DNA replication ATP-dependent helicase domain, both of which contribute to its role in DNA metabolism . When selecting DNA2 antibodies for research, it's important to consider which domain or region they target, as this may affect detection of specific functions. Available commercial antibodies may target different regions of the protein, including internal regions or specific amino acid sequences . For example, some antibodies are designed to recognize the middle region of DNA2L (such as ARP36549_P050), while others may target internal amino acid sequences as specified in their immunogen information . This domain-specific targeting can be particularly important when studying how different functions of DNA2 contribute to cellular processes or when attempting to block specific activities of the protein in experimental settings.

What are the optimal conditions for using DNA2 antibodies in Western blotting?

For optimal results in Western blotting with DNA2 antibodies, several methodological considerations are essential. Based on validated protocols, researchers should typically use a dilution range of 1:500 to 1:1000 for most commercially available DNA2 antibodies . Sample preparation is critical: total protein lysates from tissues such as mouse liver or thymus have been successfully used as positive controls . For cell lines, those with known DNA2 expression (such as HepG2) are recommended. The large size of DNA2 protein (approximately 120.4 kDa) requires special attention to gel percentage and transfer conditions—using lower percentage gels (6-8%) and longer transfer times improves detection of this higher molecular weight protein. When optimizing the protocol, researchers should test different blocking solutions (typically 5% non-fat dry milk or BSA in TBST) to minimize background while maintaining specific signal intensity. After primary antibody incubation (typically overnight at 4°C), thorough washing steps (at least 3-4 times for 5-10 minutes each with TBST) are crucial for reducing non-specific binding. The detection method should be chosen based on expected expression levels—chemiluminescence offers good sensitivity for DNA2 detection, while fluorescent secondary antibodies may provide better quantification capabilities.

How should DNA2 antibodies be used in immunofluorescence and immunohistochemistry applications?

When utilizing DNA2 antibodies for immunofluorescence (IF) or immunohistochemistry (IHC), specific protocol optimizations are necessary to achieve reliable and reproducible results. For IF applications, a dilution range of 1:200 to 1:800 is typically recommended based on validated protocols, while IHC applications generally require a dilution range of 1:50 to 1:500 . Fixation method significantly impacts antibody performance—for IF with cell lines such as HepG2, 4% paraformaldehyde fixation for 15-20 minutes at room temperature generally provides good results. For IHC applications with formalin-fixed paraffin-embedded tissues, antigen retrieval is critical; protocols suggest using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may serve as an alternative . Blocking is essential to reduce background staining—5% normal serum from the species of the secondary antibody in PBS with 0.1-0.3% Triton X-100 for 1 hour at room temperature works well for both applications. For visualization in IF, fluorescent secondary antibodies compatible with the primary antibody host species (typically anti-rabbit) should be selected, while for IHC, either HRP-conjugated secondary antibodies with DAB substrate or fluorescent secondaries may be used depending on the desired detection method. Human cervical cancer tissue has been documented as a positive control for IHC applications with DNA2 antibodies .

What controls should be included when working with DNA2 antibodies?

Implementing appropriate controls is essential for validating experimental results and ensuring the specificity and reliability of DNA2 antibody applications. Positive controls should include tissues or cell lines with documented DNA2 expression—mouse liver tissue, mouse thymus tissue, and HepG2 cells have been validated as suitable positive controls for various applications . In addition to positive tissue controls, researchers should consider running parallel experiments with recombinant DNA2 protein at known concentrations to establish a standard curve for quantitative analyses. Negative controls are equally important: samples where primary antibody is omitted but all other reagents are included helps identify non-specific binding of secondary antibodies, while isotype controls (non-specific antibodies of the same isotype and host species) help distinguish between specific binding and Fc receptor interactions. For definitive validation of antibody specificity, knockdown/knockout controls provide the most rigorous assessment—cells with DNA2 expression reduced through siRNA, shRNA, or CRISPR-Cas9 technology should show corresponding reduction in signal intensity. Published literature reports at least 8 studies utilizing DNA2 knockdown/knockout approaches to validate antibody specificity . Additionally, peptide competition assays, where the antibody is pre-incubated with the immunizing peptide before application to samples, can confirm binding specificity when signal reduction occurs.

How can DNA2 antibodies be used to study DNA replication stress and genome stability?

DNA2 antibodies serve as powerful tools for investigating replication stress and genome stability through multiple sophisticated methodological approaches. Immunoprecipitation (IP) using DNA2 antibodies (recommended at 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) allows researchers to isolate DNA2 protein complexes and identify interacting partners involved in replication fork protection . This approach has revealed that DNA2 plays critical roles in stalled replication fork protection, as documented in recent research publications . Chromatin immunoprecipitation (ChIP) assays using DNA2 antibodies help determine the genomic locations where DNA2 associates with DNA, particularly at sites of replication stress. For studying the dynamics of replication stress responses, combining DNA2 immunofluorescence with markers of replication stress (such as γH2AX or RPA) in synchronized cell populations provides spatiotemporal insights into DNA2 recruitment. Researchers can employ proximity ligation assays (PLA) with DNA2 antibodies in combination with antibodies against other replication and repair factors to visualize and quantify protein-protein interactions at stalled replication forks in situ. When examining how DNA2 contributes to replication fork stability under stress conditions, DNA fiber assays performed after DNA2 depletion or inhibition, validated by immunoblotting with DNA2 antibodies, demonstrate the functional consequences of DNA2 loss on replication dynamics.

What is the role of DNA2 in homologous recombination, and how can antibodies help elucidate this function?

DNA2 plays a crucial role in homologous recombination (HR) repair by facilitating the recruitment of HR repair factors, such as Rad51, to double-strand breaks (DSBs) and preparing DNA ends for homologous sequence invasion through its nuclease activity . Researchers can employ DNA2 antibodies in immunofluorescence studies to visualize the recruitment of DNA2 to DNA damage sites induced by ionizing radiation or radiomimetic drugs, typically using a dilution of 1:200-1:800 . Dual immunostaining with DNA2 antibodies and antibodies against key HR proteins (like RAD51, BRCA1, or RPA) enables the characterization of temporal recruitment patterns and colocalization at repair foci. For biochemical validation of DNA2's role in HR, researchers can perform co-immunoprecipitation experiments using DNA2 antibodies (0.5-4.0 μg for IP) to identify protein interactions within the HR machinery . DNA end resection assays, which measure the generation of single-stranded DNA at break sites, can be combined with DNA2 antibody-mediated knockdown validation to directly assess DNA2's functional contribution to HR. Recent research has demonstrated that DNA2 plays an important role in preventing alternative non-homologous end joining by facilitating proper DNA-end resection . When studying HR deficiency in cancer contexts, immunohistochemical analysis using DNA2 antibodies (at 1:50-1:500 dilution) on patient-derived samples helps correlate DNA2 expression levels with HR competency and potential therapeutic vulnerabilities .

How are DNA2 antibodies used in investigating cancer therapeutic strategies involving DNA2 inhibition?

DNA2 antibodies serve as essential tools in developing and validating cancer therapeutic strategies centered on DNA2 inhibition. Recent research has identified DNA2 inhibitors, including a novel compound referred to as d16, as potential synthetic lethal targeted therapies for cancers harboring mutant p53 . Researchers use Western blotting with DNA2 antibodies (at 1:500-1:1000 dilution) to confirm the correlation between DNA2 expression levels and sensitivity to DNA2 inhibitors across cancer cell lines . For mechanistic studies, DNA2 antibodies in immunofluorescence applications (at 1:200-1:800 dilution) help visualize changes in DNA2 localization and interaction with repair factors following inhibitor treatment . Combining DNA2 inhibitors with PARP inhibitors represents a promising therapeutic strategy that extends beyond BRCA-mutated cancers; DNA2 antibodies are crucial for validating the synergistic effects by confirming DNA2 targeting and downstream effects on HR repair capacity. In patient-derived xenograft models, immunohistochemistry using DNA2 antibodies (at 1:50-1:500 dilution) helps assess DNA2 expression levels before and after treatment, correlating expression with treatment response . For translational research, tissue microarray analysis with DNA2 antibodies helps identify cancer patient populations most likely to benefit from DNA2-targeted therapies based on expression patterns and association with clinical outcomes, such as the documented poor prognosis in ovarian cancer patients with DNA2 overexpression .

What are common challenges when using DNA2 antibodies and how can they be addressed?

Researchers frequently encounter several methodological challenges when working with DNA2 antibodies across various applications. One primary issue is high background signal in immunoblotting, which can be addressed by optimizing blocking conditions (testing both 5% BSA and 5% non-fat milk in TBST), increasing washing duration and frequency (5-6 washes of 10 minutes each), and testing more stringent washing buffers (increasing Tween-20 concentration to 0.1-0.2%). For weak or absent signals in Western blots, researchers should first verify sample preparation—DNA2 is a relatively large protein (120.4 kDa) that may require special transfer conditions such as longer transfer times or lower percentage gels (6-8%) . Additionally, antibody concentration may need adjustment beyond the standard 1:500-1:1000 dilution range, or alternative antibodies targeting different epitopes might provide better detection . Cross-reactivity with unintended proteins represents another challenge; comparing results from multiple DNA2 antibodies targeting different epitopes can help confirm specificity, while validating with known positive controls (mouse liver or thymus tissue) and negative controls (DNA2 knockdown samples) increases confidence in specific detection . For immunohistochemistry applications, antigen retrieval is particularly critical—while TE buffer at pH 9.0 is recommended, some tissues may require optimization with alternative buffers such as citrate buffer at pH 6.0 .

How should researchers optimize DNA2 antibody protocols for different cell lines and tissue types?

Optimizing DNA2 antibody protocols for diverse experimental materials requires systematic adaptation of key parameters. When transitioning between different cell lines, preliminary titration experiments are essential—though recommended dilutions provide starting points (1:500-1:1000 for WB, 1:200-1:800 for IF, and 1:50-1:500 for IHC), optimal concentrations may vary significantly between cell types . The fixation method substantially impacts antibody performance in IF and IHC applications—while 4% paraformaldehyde works well for most cultured cells, tissue samples may require more extensive fixation optimization. For formalin-fixed paraffin-embedded tissues, antigen retrieval conditions should be systematically tested; while TE buffer at pH 9.0 is recommended for DNA2 antibodies, some tissues may respond better to citrate buffer at pH 6.0 or other retrieval methods . When working with tissues known to express high levels of DNA2, such as proliferating tissues or certain cancer types, titrating to lower antibody concentrations may help prevent signal saturation and enable better visualization of expression differences. For tissues with potentially low DNA2 expression, signal amplification systems (such as tyramide signal amplification or polymer-based detection systems) may improve sensitivity while maintaining specificity. Cross-validation across multiple detection methods provides increased confidence—for example, confirming IF findings with Western blot analysis using the same antibody helps ensure that observed signals represent authentic DNA2 expression patterns.

What quantification methods are recommended for DNA2 expression analysis in research settings?

Accurate quantification of DNA2 expression requires appropriate methodological approaches tailored to specific experimental contexts. For Western blot quantification, densitometric analysis of band intensity normalized to loading controls (such as β-actin, GAPDH, or total protein staining) is recommended, with multiple biological replicates (minimum n=3) to account for natural variation . When comparing DNA2 expression across multiple samples, inclusion of a standard curve using recombinant DNA2 protein at known concentrations enables more precise absolute quantification. In immunohistochemistry applications, several quantification approaches are valid: (1) H-score method, which combines staining intensity (0-3) with percentage of positive cells (0-100%) to generate scores ranging from 0-300; (2) Allred scoring system, which sums intensity score (0-3) and proportion score (0-5) to create values from 0-8; or (3) digital image analysis using software platforms that can objectively quantify staining intensity and distribution. For immunofluorescence quantification, integrated density measurements (product of area and mean gray value) provide robust data when comparing nuclear versus cytoplasmic DNA2 localization or expression levels between experimental conditions. When performing RT-qPCR to complement protein-level analyses, researchers should design primers spanning exon-exon junctions to avoid genomic DNA amplification and normalize to multiple reference genes validated for stability in the experimental system. For comprehensive expression profiling across multiple samples, techniques like tissue microarray analysis with DNA2 antibodies enable high-throughput quantitative comparison while minimizing technical variables.

How are DNA2 antibodies being used to explore the relationship between DNA2 and cancer progression?

DNA2 antibodies are enabling sophisticated investigations into the complex relationship between DNA2 and cancer progression through multiple methodological approaches. Immunohistochemical analysis of patient tissue microarrays using DNA2 antibodies (at 1:50-1:500 dilution) has revealed that DNA2 is frequently overexpressed in various cancer types, particularly in tumors harboring mutant p53, and this overexpression correlates with poor clinical outcomes in ovarian cancer . Researchers employ DNA2 antibodies in chromatin immunoprecipitation sequencing (ChIP-seq) experiments to map DNA2 binding sites across the genome in normal versus cancer cells, providing insights into how altered DNA2 function contributes to genomic instability driving cancer evolution. For mechanistic studies, co-immunoprecipitation using DNA2 antibodies (0.5-4.0 μg per IP reaction) helps identify cancer-specific protein interactions that may represent vulnerabilities for therapeutic targeting . Dual immunofluorescence staining with DNA2 antibodies (1:200-1:800 dilution) and markers of replication stress or DNA damage enables spatial analysis of how DNA2 contributes to managing the elevated replication stress characteristic of many cancers . In functional studies, researchers use DNA2 antibodies to validate knockdown efficiency before assessing the impact on cancer hallmarks like invasion, migration, and resistance to therapy. Recent research has demonstrated that DNA2 inhibition represents a promising synthetic lethal approach for treating cancers with mutant p53, indicating that DNA2 expression analysis with antibodies may serve as a predictive biomarker for response to emerging targeted therapies .

What recent methodological advances have improved the utility of DNA2 antibodies in research?

Recent technological and methodological advances have significantly enhanced the utility of DNA2 antibodies across various research applications. Super-resolution microscopy techniques (such as STORM, PALM, or SIM) combined with highly specific DNA2 antibodies now allow visualization of DNA2 localization at unprecedented nanoscale resolution, revealing precise spatial relationships with other repair factors at individual replication forks or DNA damage sites. Proximity-based labeling techniques, including BioID and APEX2, coupled with DNA2 antibodies for validation, enable unbiased identification of proteins that interact with DNA2 in living cells under various conditions, expanding our understanding of DNA2's functional interaction network. Advances in single-cell analysis platforms now allow researchers to use DNA2 antibodies to quantify expression heterogeneity within tumors or tissues, correlating expression at the individual cell level with other markers of interest. CRISPR-Cas9 gene editing combined with precise epitope tagging of endogenous DNA2 has facilitated the development of highly specific antibodies against tag sequences, circumventing issues with direct DNA2 antibody specificity while allowing normal physiological expression levels to be maintained. Mass cytometry (CyTOF) using metal-conjugated DNA2 antibodies enables simultaneous analysis of DNA2 expression alongside dozens of other proteins in single cells, providing comprehensive phenotypic profiles in heterogeneous populations. These methodological advances collectively enhance research capabilities, allowing more precise characterization of DNA2's roles in normal biology and disease states.

How might DNA2 antibodies contribute to developing personalized cancer treatments?

DNA2 antibodies are poised to make significant contributions to personalized cancer medicine through multiple translational research applications. Immunohistochemical analysis of tumor biopsies using DNA2 antibodies (at 1:50-1:500 dilution) can identify patients with DNA2 overexpression who might benefit from emerging DNA2 inhibitors or combination therapies, such as the synthetic lethal approach for mutant p53-bearing cancers . This approach could be particularly valuable for ovarian cancer patients, where DNA2 overexpression correlates with poor outcomes . For monitoring treatment response, serial biopsies analyzed with DNA2 antibodies can track changes in expression or subcellular localization following therapy, potentially serving as pharmacodynamic biomarkers of target engagement. Researchers are developing companion diagnostic assays using DNA2 antibodies to identify patients likely to respond to DNA2 inhibitors alone or in combination with PARP inhibitors, potentially extending the benefit of PARP inhibitors beyond the current 15% of breast and ovarian cancers with BRCA mutations . In liquid biopsy applications, detection of DNA2 in circulating tumor cells or extracellular vesicles using highly sensitive DNA2 antibodies could provide non-invasive monitoring of tumor status and therapeutic response. For resistance mechanism studies, DNA2 antibodies help characterize how changes in DNA2 expression or localization contribute to therapy resistance, informing strategies to overcome or prevent resistance. As multiplexed immunofluorescence platforms continue to develop, DNA2 antibodies will be incorporated into panels that simultaneously assess multiple DNA repair factors, enabling comprehensive pathway analysis for precision medicine approaches.